Scientific narrative
A defensible scientific spine every asset can pull from.
Shortlist it, send it over — we come back with the shape we'd actually recommend.
What scientific narrative actually is.
The scientific platform every other asset borrows from. A core claim, a small set of pillar claims and the supporting proof points underneath them, written as one short document the cross-functional team can argue with and sign.
Built for medical-led teams who need their commercial, access and HEOR colleagues working from the same story rather than improvising parallel versions per audience. The narrative is the spine; the slide deck, the dossier and the field tools all hang off it.
- Locked scientific narrative v1.0 with core, pillar and supporting claims
- Audience message map (clinician, payer, patient, internal) anchored to the same spine
- Evidence anchors per claim with strength and source
- Trade-off register: what we decided to lead with, what we held back and why
- Cross-functional read-out and a written handover the medical team can run from
Add the pieces you'd want and we'll build a shortlist you can review, reorder and send over. No pricing wall, no commitment — we come back with what we'd actually recommend, including anything you don't need.
Approach, modules, delivery.
Move through the tabs to see how the work runs, what it's made of and what lands at the end.
Inputs
- Trial data, mechanism-of-action papers and existing scientific decks
- Guideline and competitor narrative scans
- Medical, regulatory and commercial leadership interviews
Method
We build a claim hierarchy from the strongest scientific evidence outward. Each claim is tagged with its evidence tier, the audience it most matters to, and the downstream assets it feeds (medical slide deck, payer dossier, congress communications). The result is a single scientific spine every downstream asset can pull from without re-litigating its content.
Assumptions
- The underlying clinical evidence base supports the claims being made.
- Cross-functional teams will adopt a single source of truth if maintained.
Limitations
- Narratives age, expect to refresh when major trials read out or guidelines change.
- Scientific spine ≠ promotional message; downstream commercial assets still need their own legal/regulatory review.
Think this belongs in your scope?
Add it alongside anything else that fits, then send the shortlist over. We'll reply with the shape we'd recommend — sequence included, and the parts we think you can skip.
Build what comes next.
Whether you need growth, answers or capability, VISFO helps you move earlier and faster.